Close menu

August 2nd, 2023 | 09:15 CEST

Well positioned for the future - BioNTech, Defence Therapeutics, Sanofi

  • Biotechnology
  • Pharma
  • AI
Photo credits:

There is currently a lot of movement in the capital-intensive biotech sector. After second-tier companies, in particular, were hit hard by the effects of tighter monetary policy last year and at times traded below their cash levels, many are now considered hot takeover candidates thanks to their innovative technologies. The well-heeled pharma giants must act to avoid missing out on future blockbusters.

time to read: 3 minutes | Author: Stefan Feulner

Table of contents:

    BioNTech - Jumping on the AI train

    Once before, the Mainz-based biotech company found itself in the right place at the right time, namely with its vaccine Comirnaty. Despite the now almost forgotten Corona pandemic, the drug, which was marketed together with US partner Pfizer, flushed billions into the vaults of the "Goldmine 12". As of December 31, 2022, BioNTech's cash balance stood at EUR 13.9 billion.

    Naturally, part of this is to go into research and development, with around EUR 2.6 billion planned for the current fiscal year. In total, spending and investments for 2023 are expected to amount to around EUR 4 billion. With the final acquisition of the AI company InstaDeep, the largest merger in the still-young history of the Company has now been signed and sealed. The purchase price was around EUR 500 million in cash plus BioNTech shares. In addition, outstanding performance-based payments are to follow, according to the Company.

    InstaDeep will henceforth operate as a global subsidiary of BioNTech based in the United Kingdom. In addition to ongoing projects on behalf of BioNTech, the UK-based company will continue to provide services to clients in various industries worldwide, including technology, transportation, logistics, industrial and financial services. Through this transaction, BioNTech gains access to an employee base of approximately 290 highly skilled professionals who bring expertise in artificial intelligence, machine learning, bioengineering, data science and software development.

    Sanofi - End announced

    The BioNTech stock did not move much, with only a 2% increase after entering the field of artificial intelligence, due to the second, rather negative news of the day. Accordingly, the French pharmaceutical company and BioNTech decided to terminate the further development of BNT131, a mixture of four mRNAs that were being researched together as an intratumoral cancer therapy and brought into a subsequently extended Phase I clinical trial.

    A press release from Sanofi, which was formed in 2004 by the merger of Sanofi-Synthélabo and Aventis, stated that "Sanofi and BioNTech have jointly decided to terminate the development of the mRNA encoding cytokines SAR441000 as an intratumoral therapy based on the results of the interim analysis."

    At the end of the last stock market week, the French company delivered second quarter figures reporting lower sales and operating profit due to unfavorable exchange rates. In the period under review, Sanofi reported a slight decline in sales of 1.5% to just under EUR 9.97 billion, despite successful business with products such as the blockbuster Dupixent and vaccinations. Taking into account constant exchange rates, the increase in sales would have been 3.3%.

    The Company's adjusted operating profit also decreased slightly to EUR 2.7 billion. Following the publication of the figures, US bank JPMorgan reiterated its price target of EUR 105 with an "overweight" rating. In contrast, the experts at Deutsche Bank Research maintained their "sell" rating with a price target of EUR 90.

    Defence Therapeutics - Milestone reached

    A scalable platform technology forms the basis for Defence Therapeutics' plans this year, including two Phase I studies targeting cancer and anticipated key results from a comparative study on mRNA vaccines. The Canadian biotech company is committed to developing next-generation vaccines and ADC products using its proprietary and patented Accum™ technology. It has the distinct advantage of ensuring the precise transport of vaccine antigens or ADCs in intact form to target cells, significantly improving efficiency and, thus efficacy against diseases such as cancer or infectious diseases.

    Defence Therapeutics also set a milestone in the cooperation agreement with the French specialists in nuclear medicine, Orano. In the first step, an active ingredient from Orano was successfully linked to Accum™ and made usable. The following milestones include synthesising a second AccuTOX™ variant containing a cathepsin B-dependent cleavable sequence. The goal here is to develop radiotherapy with improved efficacy by combining the intracellular drug delivery expertise of Defence Therapeutics with the radiochemical know-how provided by Orano. The market for radiopharmaceuticals alone is enormous. Market analysis firm The Insight Partners forecasts that the market volume is expected to grow from USD 7.55 billion in 2021 to USD 13.818 billion by 2028 at an annual growth rate of 9.0%.

    Defence Therapeutics' market capitalization is currently CAD 124.49 million. Should the Company stay on schedule and start the planned Phase I trials this year, the stock, currently trading at CAD 2.85, should leave behind its current high for the year at CAD 4.85. You can read an in-depth interview with Defence Therapeutics CEO Sébastien Plouffe here.

    BioNTech is investing in the future with the acquisition of UK AI company InstaDeep. In contrast, the BNT131 development collaboration with Sanofi has been halted. Defence Therapeutics is expected to shine this year with a continuous news flow and should move into higher regions if Phase I trials start successfully.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST

    Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets

    • Biotechnology
    • Pharma
    • Electromobility

    Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.


    Commented by André Will-Laudien on September 18th, 2023 | 06:30 CEST

    Unbelievable! Hands off AI, biotech in rebound! Bayer, Defence Therapeutics, Morphosys

    • AI
    • Biotechnology
    • Investments

    The big fall decline is now over. It is always a difficult time, but the so-called "Triple Witching" went relatively smoothly this time. The European Central Bank (ECB), in its first interest rate meeting after the summer break, decided to raise key rates by another quarter point to 4.00%, up from the previous 3.75% in July. At the same time, it lowered its inflation forecast for 2025 and the outlook for economic growth in the Eurozone for the years 2023 to 2025. Economic risks are increasing, but inflation remains the determining factor for interest rates. Expectations that the US Federal Reserve (FED) will announce an interest rate pause at its next meeting on Wednesday have boosted confidence. Last week's big losers were the recently favoured AI stocks Nvidia, Microsoft and However, the biotech sector has recently started to climb again. Where are the opportunities for investors?


    Commented by André Will-Laudien on September 14th, 2023 | 09:05 CEST

    Artificial Intelligence in practice? Nvidia, NorCom, Palantir - The next 100% with Big Data

    • AI
    • Software
    • Investments

    The stock market is not a one-way street. Investors are trying to ride the wave of "Artificial Intelligence" (AI), and corresponding stocks such as, Nvidia, Microsoft, or Palantir are performing well in 2023. A new megatrend is underway here, which, according to experts, will continue for several years. However, because of the high valuations in the entire sector, it is worth taking an analytical look. After all, no one knows how long the AI boom will continue to generate decent returns on the stock market. Opportunity-rich stocks still exist in the second and third tier. We are taking a closer look.